SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

AstraZenecas reported Baxfendy sales have traders questioning how quickly the new aldosterone-inhibitor class can gain coverage and commercial traction, weighing on expectations for Mineralys planned launch. Some see the early sales as a normal reimbursement ramp for a chronic treatment, while others worry that a slow launch and competition could constrain lorundrostats sales potential.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

The FDAs accelerated approval of Inovios competing RRP treatment, Voceryq, has raised concerns about pressure on Precigens PAPZIMEOS sales. Traders debate the competitive threat against PAPZIMEOSs first-mover position and full approval, while some question Inovios ability to commercialize its drug and note its confirmatory-study requirement.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Discussion centers on Zebecs reported payroll and payments integrationsincluding MoneyGram/Stellar, European deployments, and Robinhood Chain supportwhich traders see as potential drivers of adoption and ZBCN demand. Others question whether these partnerships will translate into meaningful token use, noting the coins weak or uneven price performance; some rumored connections remain unconfirmed.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIMs raised full-year outlook amid strong shipping demand and elevated freight rates is fueling expectations for stronger profits and dividends. Traders are also debating the uncertain Hapag-Lloyd takeover, with Israeli regulatory opposition raising the possibility the deal could be delayed or fail.

Compound (COMP) is a cryptocurrency and operates on the Ethereum platform. Compound has a current supply of 10,000,000 with 9,999,999.99995246 in circulation. The last known price of Compound is 20.49527411 USD and is down -2.02 over the last 24 hours. It is currently trading on 652 active market(s) with $25,001,434.49 traded over the last 24 hours. More information can be found at https://www.compound.xyz/.

Compound

Compounds institutional-market rollout and broader institutional push are the main focus, with traders linking the effort to potential growth in DeFi and tokenized assets. Some see it as a catalyst for COMP, while others remain frustrated that the token has lagged the wider crypto market.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

A sharp pullback to a month low and a break below key technical levels are driving discussion, with traders debating whether call-heavy options activity signals dip buying or is simply catching a falling stock. Sentiment is split between buyers hoping support holds and bearish traders watching for further downside.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Strong earnings and growing natural-gas demand from AI data centers are driving bullish discussion, alongside Energy Transfers rising distributions. Many investors see its pipeline network as well positioned for that demand, while others are frustrated by muted unit-price action and cite interest rates, energy-market volatility, or the Texas Stock Exchange listing move as potential headwinds.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has surged to a fresh 52-week high ahead of its Q3 earnings, with traders weighing expected BRIUMVI sales growth against unconfirmed buyout speculation. Heavy short-interest and call-option activity are also fueling short-squeeze chatter, though some investors argue the rally is positioning for earnings rather than a takeover.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devons agreed sale of its Eagle Ford assets to Crescent is driving attention, following earlier speculation about asset divestitures and pressure to streamline the company after its Coterra merger. Traders are divided on whether the sale improves focus and capital allocation, with some questioning why the shares have not responded more strongly.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick shares are drawing attention amid a pullback in gold miners, with traders pointing to mostly put-heavy options activity and bearish chart analysis that suggests the correction may not be over. Others view the weakness as a buying opportunity, citing the longer-term gold and copper outlook and continued accumulation in the mining sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioCardia Shares Fall 10% After Hours: Here's Why

BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.read more...

BioCardia (BCDA) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

New Strong Sell Stocks for July 28th

LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.

New Strong Sell Stocks for July 14th

AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.

What's Going On With BioCardia Stock Tuesday?

BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check out the vital levels to watch.read more...

Why Did BCDA Stock Surge More Than 50% Today?

Equity

 BioCardia said the U.S. Food and Drug Administration confirmed that its ongoing CardiAMP Heart Failure II study could support a premarket approval application for its cell therapy.

Why Is BioCardia Stock Gaining Friday?

BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.read more...

Biotech Stocks Are Loading Up on Major 2026 Catalysts and Wall Street Is Watching

Investors continue to focus on companies capable of generating meaningful clinical milestones, regulatory achievements, and commercial opportunities in large underserved markets. Several small-cap healthcare names now have potentially market-moving events scheduled throughout the remainder of 2026, positioning them among closely watched stocks in the biotech and healthcare sectors. $BCDA, $NTHI, $MTVA, $BGMS, $CMND

BioCardia (BCDA) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

BioCardia Q1 2026 Earnings Call: Complete Transcript

Reported GAAP EPS of -$0.13 up 67.50% YoY

BioCardia faces substantial doubt regarding its ability to continue as a going concern beyond January 2027, given recurring net losses, an accumulated deficit of $172.2 million, and limited cash resources.

BioCardia is advancing its clinical programs with positive regulatory progress from the FDA and Japan's PMDA, while securing additional intellectual property protection for its Heart3D Fusion Imaging technology platform.

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

BioCardia Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>The treatment is for patients with ischemic heart failure with reduced ejection fraction, a serious condition affecting more than one million people in the U.S.</li><li>BioCardia is preparing to submit an approval application for its cell therapy in Japan in the fourth quarter of 2026.</li><li>BCDA shares jumped past their 200-day moving average for the first time since September 2025.</li></ul>BioCardia (BCDA) surged back into investors’ radar on Friday, as a promising U.S. Food and Drug Administration indication for the company’s cell therapy to treat a type of serious heart condition boosted the stock past 50% to its highest levels in more than eight months.<a href="https://stocktwits.com/symbol/BCDA">BCDA shares</a> recorded their biggest single-day gains since August 2024 and also breached their 200-day moving average (200-DMA) for the first time since last September.<h2 class="st-heading-2">BCDA’s Heart Failure Study Could Support Premarket Application</h2>BioCardia said the FDA confirmed that its ongoing CardiAMP Heart Failure II study could support a Premarket Approval (PMA) application for the therapy. A PMA is the FDA’s review process for high-risk medical products and is required before they can be marketed in the United States.The treatment is designed for patients with ischemic heart failure with reduced ejection fraction, a serious condition that affects more than one million people in the U.S. CardiAMP uses a patient’s own bone marrow cells, which are delivered to the heart through a minimally invasive catheter procedure.The therapy has already received FDA Breakthrough Device designation. BioCardia said the FDA recognized both the unmet need for new heart failure treatments and the strength of data from its earlier CardiAMP clinical study.BioCardia is preparing to submit an approval application for its cell therapy in Japan in the fourth quarter of 2026.<h2 class="st-heading-2">What Is Retail’s Take On BCDA?</h2>Retail sentiment for BCDA on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, with ‘extremely high’ message volumes.One user said a “huge breakthrough” in heart failure treatment could be on the horizon.<stembedurl>https://stocktwits.com/GJ_Rockabilt/message/655556587</stembedurl>Another user highlighted the “huge” market potential of the therapy.<stembedurl>https://stocktwits.com/bergini/message/655546626</stembedurl>More than 109 million shares changed hands, compared to the daily average of around 371,000, according to Stocktwits data.Friday’s super-rally has driven the stock up by around 9% in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/pl-stock-sinks-on-stock-offering-margin-compression/cZ0FVCWReCL">PL Stock Records Sharpest Single-Day Fall In 21 Months – Why Bullish Street Calls, Earnings Beat Failed To Turn The Tide</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Tema Heart & Health ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.861
Prev Close	$0.926
Open	$0.9384
Dividend Yield	0.00%
50-Day Moving Average	$1.05
Beta	0.86
Avg. Volume	347,246.69
PE Ratio	-1.13

52-Week High	$1.80
52-Week Low	$0.75
Market Capitalization	$13.03M
EPS (Annual)	-$1.23
Price to Book	4.78
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCDA Fundamentals